Compare Quest Diagnostics Inc (DGX) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs H2O America — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while H2O America trades at $62.3 (market cap $2.61B). The key difference: Quest Diagnostics Inc is far larger — about 10× H2O America's market cap, and H2O America pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| DGX | HTO | |
|---|---|---|
Market Cap | $26.21B | $2.61B |
Sector | Health | Technology |
52-Week High | $238.50 | $65.43 |
52-Week Low | $173.49 | $44.44 |
Enterprise Value | $31.97B | $4.40B |
Dividend Yield | 1.45% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
HTO trades at $62.42, up 1.92% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a 12.91% net income margin and consistent earnings beats in recent quarters. Recent news highlights transformative acquisitions in Texas, though dilution risks exist. Institutional interest is strong, with Fifth Third Bancorp increasing its stake by 3,753.2% in Q1 2026 (SEC filing, 2026-07-30).
Outlook is positive with an 83.33% analyst buy rating and a consensus price target of $69.50, implying ~11% upside. Risks include execution challenges from acquisitions and potential EPS pressure from equity issuance. The dividend yield remains supported, but growth sustainability depends on operational efficiency amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
